bluebird on track to submit MAA to EMA for LentiGlobin

bluebird bio Inc. (NASDAQ:BLUE) said it is on track to submit an MAA to EMA next half for its LentiGlobin BB305 to treat beta-thalassemia and reported additional data from three studies of the gene therapy. LentiGlobin BB305 comprises autologous CD34+ stem cells transduced ex vivo with a lentiviral vector

Read the full 492 word article

User Sign In